Betaprosalic Ointment

Land: Malaysia

Språk: engelsk

Kilde: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Aktiv ingrediens:

Betamethasone Dipropionate (Micronised); SALICYLIC ACID

Tilgjengelig fra:

Noripharma Sdn. Bhd.

INN (International Name):

Betamethasone Dipropionate (Micronised); SALICYLIC ACID

Enheter i pakken:

10 gm; 15 gm

Produsert av:

Noripharma Sdn. Bhd.

Informasjon til brukeren

_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
_ _
BETAPROSALIC OINTMENT
Betamethasone Dipropionate, Salicylic Acid (0.05%w/w, 3.00%w/w)
1
WHAT IS IN THIS LEAFLET
1.
What is Betaprosalic Ointment
used for
2.
How
Betaprosalic
Ointment
works
3.
Before
you
use
Betaprosalic
Ointment
4.
How
to
use
Betaprosalic
Ointment
5.
While you are using it
6.
Side effects
7.
Storage
and
Disposal
of
Betaprosalic Ointment
8.
Product Description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
WHAT
BETAPROSALIC
OINTMENT
IS
USED FOR
Betaprosalic Ointment is indicated
for
relief
from
inflammatory
manifestations of hyperkeratotic and
dry
corticosteroid
responsive
dermatoses. This includes:

Psoriasis
(skin
condition
that
causes
red,
flaky,
crusty
patches
of
skin
covered
with
silvery scales).

Chronic
Atopic
Dermatitis
(condition that makes the skin
red and itchy).

Neurodermatitis (skin condition
that begins with an itch).

Lichen planus (non-infectious,
itchy rash that can affect many
areas of the body).

Eczema (term for a group of
medical
conditions
that
cause
the skin to become inflamed or
irritated).

Dyshidrosis (is a skin condition
in which blisters develop on the
soles of feet and/or the palms
of hands)

Seborrheic
dermatitis
of
the
scalp
(common,
inflammatory
skin condition that causes flaky,
white
to
yellowish
scales
to
form on oily areas such as the
scalp.
It
can
occur
with
or
without reddened skin).

Ichthyosis
vulgaris
(skin
condition that causes dry, dead
skin
cells
to
accumulate
in
patches on the surface of the
skin).

Other ichthyotic (a congenital,
often
hereditary
skin
disease
marked by dry, thickened, scaly
skin) conditions.
HOW BETAPROSALIC OINTMENT WORKS
Betaprosalic Ointment contains two
active
ingredients
which
are
betamethasone
dipropionate
and
salicylic acid
Betamethasone dipropionate belongs
to a group of medicines known as
topical corticosteroids. It is classified
as
‘potent
corticosteroid’.
These
medicines are put on the surface of
the skin to reduce the

Preparatomtale

BETAPROSALIC OINTMENT
COMPOSITION
Each gram of the ointment contain Betamethasone dipropionate
(Micronised) equivalent to 0.5
mg of Betamethasone and Salicylic acid 30mg
PRODUCT DESCRIPTION
A white to pale yellow, smooth ointment.
PHARMACODYNAMICS
Betaprosalic
preparations
contain
the
dipropionate
ester
of
betamethasone
which
is
a
glucocorticoid exhibiting the general properties of corticosteroids,
and salicylic acid which has
keratolytic properties.
Salicylic acid is applied topically in the treatment of hyperkeratotic
and scaling conditions where
its keratolytic action facilitates penetration of the corticosteroid.
In pharmacological doses, corticosteroids are used primarily for their
anti-inflammatory and/or
immune suppressive effects.
Topical corticosteroids such as betamethasone dipropionate are
effective in the treatment of a
range
of
dermatoses
because
of
their
anti-inflammatory,
anti-pruritic
and
vasoconstrictive
actions.
However,
while
the
physiologic,
pharmacologic
and
clinical
effects
of
the
corticosteroids are well known, the exact mechanisms of their action
in each disease are
uncertain.
PHARMACOKINETICS
Salicylic acid exerts only local action after topical application.
The extent of percutaneous absorption of topical corticosteroids is
determined by many factors
including vehicle, integrity of the epidermal barrier and the use of
occlusive dressings.
Topical corticosteroids can be absorbed through intact, normal skin.
Inflammation and/or other
disease processes in the skin may increase percutaneous absorption.
Occlusive dressings substantially increase the percutaneous absorption
of topical corticosteroids.
Once absorbed through the skin, topical corticosteroids enter
pharmacokinetic pathways similar
to systemically administered corticosteroids. Corticosteroids are
bound to plasma proteins in
varying degrees, are metabolised primarily in the liver and excreted
by the kidneys. Some of the
topical corticosteroids and their metabolites are also excreted in the
bile.
INDICATION
For the relief of the inf